12:00 AM
 | 
Jun 01, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Arzerra ofatumumab regulatory update

Genmab A/S (CSE:GEN), Copenhagen, Denmark
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Product: Arzerra ofatumumab ( HuMax-CD20)
Business: Cancer
FDA's Oncologic Drugs Advisory Committee voted 10-3 to recommend accelerated approval of Arzerra ofatumumab from Genmab and GlaxoSmithKline to treat chronic lymphocytic leukemia (CLL). The advisory committee said Arzerra was...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >